Axonics® files pma supplement with fda for fourth generation rechargeable neurostimulator

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval supplement with the fda for its fourth generation rechargeable sacral neuromodulation implantable neurostimulator (ins). the fourth generation rechargeable ins reduces how frequently a patient needs to recharge their implanted device to only once every six months
AXNX Ratings Summary
AXNX Quant Ranking